IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.

IL1RAP antibody-drug conjugates effectively target primary and metastatic tumors in multiple oncofusion-driven cancers, causing tumor regression and reducing metastasis.

• Why it matters: Targeting gene fusions that drive cancer progression is crucial for developing precise therapies, especially when these targets are minimally expressed in healthy tissues, reducing potential side effects.
• What they did: Researchers engineered IL1RAP-targeting ADCs with cytotoxic payloads and tested them across various cancer models, including Ewing sarcoma, ALCL, and NTRK3+ sarcomas, demonstrating potent tumor inhibition.
• The result: The ADCs induced durable tumor regression, diminished metastasis, and showed no significant toxicity in non-human primates, supporting their potential for clinical development.